We recently published a list of 15 best shares to buy according to Jim Simons Renaissance technologies In this article, let’s take a look at where Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) is against other better shares to buy according to Renaissance technologies by Jim Simons.
Even after its passage in 2024, the investor and mathematician billionaire Jim Simons is still known as the “King How much” in coverage funds due to the extraordinary success of Renaissance technologiesYour quantitative negotiation company based in New York. After years of financial industry research, Simons realized the potential without exploiting quantitative analyzes to take advantage of market inefficiencies. This vision led him to develop an investment strategy based on data to analyze market behavior only through statistical and mathematical models. By identifying the subtle patterns and not random in financial data, the genius as much predicted future movements of the actions and generated impressive returns.
Although closed to external investors, the secret fund of the medallion of Jim Simons, a Renaissance flagship, has produced innovative results since its inception. The Medallion Fund gained impressive returns of 56.6% and 74.6% during the first Dot-Compe accident in the early 2000’s and the world financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $ 31.4 billion, placing it among the richest individuals in the world, thanks to the strong performance of the Market Market Medallion and Renaissance.
The Renaissance Technologies computer based power plant began to begin after stellar realization in 2024. The Renaissance diversified Alpha Fund 11.85% in the first two months of 2025. Both funds can maintain important positions of individual stock, as well as use future actions index and options to help manage the risk. However, the firm warns that it may be difficult to quickly undo these important stakes without affecting market prices.
For this list, we have chosen actions of the Renaissance Technologies 13f portfolio in the late quarter of 2024. These actions are also popular with elite coverage funds.
Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (Check out more details here)).
Vertex Pharmaceuticals incorporated (VRTX) is the best stock to buy according to Renaissance technologies by Jim Simons?
A pharmacist who provides a specific drug to a patient in a specialized pharmacy.
Renaissance Technologies Q4 bet: 562.6 million dollars
Number of coverage fund holders: 58
Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) is a global biotechnology company that participates in the discovery and development of small molecules medicine for the treatment of severe diseases, including cystic fibrosis.
Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) reported revenue from the first quarter, which reduced closely from consensus projections, with significant performance in sales of their medicines Alyftrek and Journal. Despite this, the company expressed confidence in future growth by increasing the lower end of its financial orientation by $ 100 million.
On May 7, Bernstein’s analysts reiterated the price of $ 462 for Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) maintaining their market rating. Analyst William Pickering urged investors to exercise patience after Vertex’s shares experienced a 10% remarkable decrease on May 6. Bernstein’s position suggests a cautious approach, with the firm that emphasized the importance of impending products launches and clinical trial results to determine the future trajectory of the company’s value.
Greenskeeper Asset Management declared the following with regard to Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) Q1 2025 Investor Letter:
“Vertex Pharmaceuticals incorporated (NASDAQ: VRTX) was our second best performer in the quarter, +20.4%. The increasing demand for its cystic fibrosis franchise (CF) continued to generate a substantial free cash flow. Vertex continues to focus on diversifying his portfolio of products and recently launched two new approved therapies: Alyftrek and Journal. Alyfretk is an improvement in VRTX’s CF portfolio, which offers a dosing regime once a day much more convenient for patients. It is important to note that it covers 31 additional CF rare mutations for which no prior treatment existed. Journal, a pain inhibitor of non -opioid acute pain, begins to increase sales as doctors gain confidence in their real world effectiveness, and since VRTX advances refund negotiations with payers. We believe that Journal has the potential to become a box office therapy, providing significant quality of life to patients. In addition, VRTX is developing chronic pain therapies that use a similar action mechanism – permobar selective sodium channels – to inhibit pain transmission of pain with few effects outside the destination. Success would be great news for shareholders, but most importantly, offering a powerful alternative to opioids and helping to combat the opioid crisis. “
Usually vrtx Rankes 7th In our list of best shares to buy according to Renaissance technologies by Jim Simons. Although we recognize VRTX’s potential as an investment, our conviction lies in the belief that some AI actions have a greater promise to obtain higher yields and do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of IA more promising than VRTX but sells less than five times, see our report on this Ia stock cheap.
